Klinikum Region Hannover GmbH

The department is evaluating new strategies to lower the risk of heart‑related events in patients with cardiovascular disease and those who also have advanced kidney impairment. Studies include low‑dose anticoagulation and intensified blood‑pressure management to improve survival and quality of life.

• Low‑dose rivaroxaban to reduce major cardiovascular events
• Optimizing hypertension therapy in high‑risk patients
• Integrated care approaches for chronic kidney disease with elevated CV risk
• Prevention of myocardial infarction and stroke in established disease

Klinikum Region Hannover conducts 27 trials with 20 investigators, highlighting a strong commitment to cardiovascular research.

Research at the site targets disorders of the gastrointestinal tract, such as eosinophilic esophagitis and idiopathic gastroparesis, aiming to relieve symptoms and improve daily functioning. Innovative agents are being tested for their ability to reduce inflammation or enhance gastric motility.

• Barzolvolimab for reducing esophageal mast cell infiltration
• Naronapride to alleviate delayed gastric emptying
• Novel oral therapies for chronic gastroparesis
• Assessment of symptom improvement in eosinophilic esophagitis

The clinic’s multidisciplinary team supports 27 active studies, reflecting a broad focus on digestive health.

The hematology‑oncology unit is advancing treatment options for blood‑cell malignancies, including acute myeloid leukemia, diffuse large B‑cell lymphoma, and multiple myeloma. Trials evaluate targeted inhibitors, immunotherapies, and combination regimens to increase remission rates and reduce toxicity.

• FLT3‑targeted agents combined with chemotherapy in AML
• Mosunetuzumab plus lenalidomide for follicular lymphoma
• Zilovertamab vedotin versus polatuzumab in DLBCL
• Revumenib added to azacitidine and venetoclax in AML
• Isatuximab‑based regimens for newly diagnosed multiple myeloma

With 27 clinical trials and a team of 20 investigators, the site is a hub for cutting‑edge hematologic research.

A wide array of solid‑tumor studies are underway, focusing on non‑small cell lung cancer, head and neck squamous cell carcinoma, and other advanced malignancies. The goal is to test novel immunotherapies, targeted agents, and combined modality approaches to extend survival and improve patient outcomes.

• Durvalumab with radiation for early‑stage NSCLC
• Osimertinib after SBRT for EGFR‑mutated NSCLC
• Rilvegostomig plus chemotherapy versus pembrolizumab in metastatic NSCLC
• Divarasib plus pembrolizumab for KRAS‑mutated NSCLC
• Immunotherapy combinations for recurrent/metastatic head‑and‑neck cancer

The department’s 27 trials, supported by 20 investigators, underline its leadership in oncology research.

Investigations into progressive lung conditions such as idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease are a priority, with studies designed to slow functional decline and enhance quality of life. Emerging oral agents are being assessed for safety and efficacy in these chronic diseases.

• BI 1015550 to reduce lung‑function decline in PF‑ILD
• BI 1819479 dose‑response evaluation in IPF
• Long‑term tolerability of oral nerandomilast in ILD patients
• Combination anti‑fibrotic therapies for progressive disease

Klinikum Region Hannover’s pulmonary research program includes 27 trials, driven by a dedicated team of 20 investigators.

The clinic is exploring innovative wound‑healing approaches for chronic skin conditions, particularly chronic venous ulcer. Topical and cellular therapies are evaluated for their ability to achieve complete closure of non‑healing wounds, offering new options for patients with limited treatment alternatives.

• Topical allo‑APZ2‑CVU for therapy‑resistant ulcers
• Stem‑cell based treatment for non‑healing venous leg ulcers
• Comparative efficacy of new topical agents in chronic ulcer care

The site’s 27 active trials, conducted by 20 investigators, reflect a comprehensive focus on dermatologic and connective‑tissue research.